An Oregon bill that would have required pharmaceutical companies to disclose details of their patient assistance programs has died after opposition from industry lobbyists, leaving a significant gap in the state's ability to understand how drug manufacturers structure charitable aid. As The Lund Report reports, the legislation aimed to bring transparency to the complex ecosystem of copay assistance cards, patient assistance foundations, and manufacturer discount programs that collectively move billions of dollars annually but operate with minimal public disclosure about eligibility criteria, actual utilization, and the relationship between assistance program design and list-price increases.

The pharmaceutical industry's successful opposition underscores the political difficulty of drug pricing transparency in Oregon. Patient assistance programs occupy an unusual position in the healthcare economy: they function as both genuine charitable aid and as strategic tools that insulate high list prices from consumer resistance. When a manufacturer offers a copay card that reduces a $500 monthly specialty drug to $10, the patient sees affordability while the insurer or PBM absorbs the inflated price. Requiring disclosure of these arrangements would have exposed the mechanics of this system, which is precisely why PhRMA and its member companies fought the bill. The industry's stated objection — "legal questions" about disclosure requirements — is a standard lobbying framework that avoids debating the policy merits by raising procedural and constitutional concerns about compelled commercial speech.

Oregon healthcare leaders and policymakers should recognize that this bill's failure preserves the status quo opacity in prescription drug economics. CCOs negotiating pharmacy benefits lack visibility into how manufacturer assistance programs interact with their formulary designs and member cost-sharing structures. Hospital pharmacies and specialty clinics that help patients access assistance programs operate with incomplete information about program sustainability and eligibility changes. Health plans cannot accurately model member out-of-pocket exposure when manufacturer programs can be modified or discontinued without notice. The Oregon Prescription Drug Affordability Board, established in 2021, continues its work on drug pricing but lacks the manufacturer-level assistance program data that this bill would have provided.

Watch for whether the Prescription Drug Affordability Board pursues this data through administrative rulemaking rather than legislation, bypassing the legislative opposition that killed the bill.